Fig 7. Testing tamoxifen-induced recombination of TgLSL-TPP1 by TgGFAP-cre/ERT2 and Tgicre/ERT2.
Six-week Tpp1+/- animals with indicated TgLSL-TPP1 and TgGFAP-cre/ERT2 (A) or Tgicre/ERT2 (B) genotypes were treated with tamoxifen as shown. Animals were killed one week after induction and assayed for TPP1 brain activity. C, 5-day old Tpp1-/- animals containing TgLSL-TPP1 with TgGFAP-cre/ERT2 were treated as indicated, killed one month after induction, and assayed for brain TPP1 activity. Tam, tamoxifen; Other transgene is TgLSL-TPP1 (TPP1 transgene with stop cassette) or TgL-TPP1 (active TPP1 transgene). The mean of each experimental condition was compared with every other mean by one-way ANOVA with p values corrected using Tukey’s multiple comparison test. No significant increase in TPP1 activity was detected under any experimental condition when animals containing both TgLSL-TPP1 and cre/ERT2 driver transgene were treated with tamoxifen compared to similar animals that were untreated or vehicle-treated.